DMSO (200 mg/ml)
Dasatinib is a multi-kinase inhibitor with potent activity against BCRABL kinase (IC50 = 0.21.1 nM). Dasatinib also inhibits Lyn (IC= 8.5 nM) and Src (IC= 3.0 nM) kinase activities in vitro using 0.1 mg/mL poly (Glu4-Tyr) as the substrate. Dasatinib is used to treat certain adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL).
Research or further manufacturing use only, not for food or drug use.